Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DR-18–modified neoantigen-reactive T cells
- Development stage
- Unknown
- Lead developer
- Changhai Hospital
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
DR-18–modified neoantigen-reactive T cells is an autologous cell therapy consisting of T cells that have been selected for reactivity against tumor-specific neoantigens and genetically modified to express a novel interleukin-18 (IL-18) variant, designated DR-18. This modification is intended to enhance the persistence, expansion, and anti-tumor activity of the T cells within the immunosuppressive tumor microenvironment. The DR-18 variant is designed to be decoy-resistant, meaning it is insensitive to neutralization by the endogenous inhibitor interleukin-18 binding protein (IL-18BP). The therapy is being developed by The First Affiliated Hospital of The Second Military Medical University (Changhai Hospital) for the treatment of advanced small cell lung cancer (SCLC).
- Other names
- DR-18-modified NRTsDR18-modified NRTsDR 18-modified NRTsIL-18-modified neoantigen-reactive T cellsIL18-modified neoantigen-reactive T cellsIL 18-modified neoantigen-reactive T cells
02
Targets
IL-18R (Interleukin-18 receptor complex)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on DR-18–modified neoantigen-reactive T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DR-18–modified neoantigen-reactive T cells.